Cipla hopes to benefit from govt push for generics

Dhuraivel Gunasekaran BL Research Bureau | Updated on January 12, 2018 Published on May 26, 2017


The stock of drug maker Cipla fell about 3 per cent today after the company reported a consolidated net loss of Rs 61.79 crore in the March 2017 quarter. However, the company has pared its loss by 25 per cent compared with the consolidated net loss of Rs 92.83 crore in the March quarter last year.

The net loss during the recent quarter was due to a one-off non-cash impairment charge of Rs 214.4 crore on litigation and regulatory developments for certain products in the US. A provision of Rs 56 crore on certain assets of its biotech subsidiary also contributed to the loss. If the non-cash charges are adjusted, the consolidated net profit would be around Rs 200 crore. The company had recorded consolidated net loss during the March quarter last year due to one-off costs related to its business in Europe and some emerging markets.

The consolidated net sales in the recent March quarter was Rs 3,487.04 crore, 7 per cent higher y-o-y, supported by higher sales from North America and South Africa.

Sales from India, which contributes about 40 per cent to Cipla’s revenue, contracted about 4 per cent y-o-y due to de-stocking at the channel level. This impacted March quarter revenues. Despite being hit hard by price control in the domestic region, the management believes that the government’s policy on pushing generic drugs will benefit the company going forward.

Sales from North America, which accounts for 15 per cent of the overall sales, grew 33 per cent y-o-y thanks to a pick-up in sales in the InvaGen portfolio. However, sequential growth was slower due to increasing pricing pressure and delays in approval of key products. Ramping up the US business by building its own front-end presence and more launches through acquisitions are expected to provide support to revenue going forward. Sales from South Africa registered strong growth of 50 per cent y-o-y during the March quarter on the back of strong growth across both the private market and tender business. The launch of Sereflo aided the UK business, which registered revenue growth of 8 per cent Y-o-Y.

For the full year 2016-17, consolidated revenue at Rs 14,630 crore was 6 per cent higher than in 2015-16. The operating margin at 17 per cent was supported by a strong performance in key markets. In 2016-17, the company had filed 32 abbreviated new drug applications (ANDA). The management expects 20-25 products to be filed in 2017-18.

At the current price, the Cipla stock trades at about 39 times the trailing 12-month earnings — a 7 per cent premium to its three-year average and about 10 per cent premium to large cap pharma peers.

Published on May 26, 2017

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.